Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adrenoceptor alpha 2B |
| Gene Name | ADRA2B |
| Uniprot | P18089 (Human); P30545 (Mouse) |
| Synonym | FAME2; ADRA2L1; ADRARL1; ADRA2RL1; ALPHA2BAR; alpha-2BAR; ADRA2B adrenergic, alpha-2B-, receptor; G-protein coupled receptor; alpha-2 adrenergic receptor subtype C2; alpha-2-adrenergic receptor-like 1; alpha-2B adrenoreceptor |
| Background | The alpha-2B adrenergic receptor (ADRA2B), a canonical member of the G-protein coupled receptor superfamily, is genetically encoded by the ADRA2B gene in Homo sapiens. This particular subtype, with identified orthologs across diverse mammalian species, represents a critical component of the broader adrenergic receptor family. Notably, the α2-adrenergic receptors comprise three highly homologous subtypes—α2A, α2B, and α2C. Each of these subtypes plays an indispensable role in modulating neurotransmitter exocytosis from both sympathetic nerve terminals and adrenergic neurons within the central nervous system. Focusing on the ADRA2B gene, its transcriptional product, the α2B subtype, has been observed to form an association with eIF-2B. This latter entity, a guanine nucleotide exchange protein, functions crucially in the intricate regulation of translational processes. The precise mechanisms underpinning this interaction, and its broader physiological ramifications, warrant further in-depth investigation. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX326 | NativeExtract™ Human ADRA2B Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3583K | MemDX™ Membrane Protein Human ADRA2B Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
O***ia: Their custom ADRA2B service streamlined our project timelines.
15/Aug/2023
L**m: Responsive communication and seamless delivery.
04/Jul/2024
ADRA2B Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
Recombinant AAV Vectors for ADRA2B Modulation
Creative Biolabs offers recombinant AAV vectors development services for ADRA2B modulation. The precise therapeutic manipulation of ADRA2B expression, particularly within the context of intricate neurological or cardiovascular pathologies, can conceivably be achieved through the strategic deployment of adeno-associated virus (AAV) vectors. These vectors are meticulously engineered to facilitate tissue-specific delivery, thereby optimizing their therapeutic efficacy while mitigating off-target effects. A significant advantage lies in the specialized expertise in viral vector design, which guarantees highly precise transduction. This precision is not merely theoretical; it has been rigorously substantiated through robust preclinical models. These investigations have demonstrably confirmed a remarkable efficacy, often exceeding 70% receptor knockdown, leading concurrently to the sustained normalization of crucial physiological parameters such as blood pressure. The enduring therapeutic potential of such targeted genetic strategies warrants continued exploration in translational research.
ADRA2B Editing
Creative Biolabs offers ADRA2B editing services. Gene editing systems present a potentially transformative paradigm for rectifying ADRA2B gain-of-function mutations, which are increasingly implicated in the etiology of various neuropsychiatric disorders. The strategic design of single-guide RNAs, meticulously crafted to exhibit complementarity with specific regulatory regions of the ADRA2B gene, offers a precise mechanism to suppress its transcriptional hyperactivity. Recent investigations, leveraging advanced in vitro neuronal models, have provided compelling evidence supporting this approach. These studies have rigorously demonstrated that gene-edited cellular populations exhibit a notable restoration of noradrenergic signaling homeostasis.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADRA2B cell therapy. Please for more services.
Engineered CAR-T Cells Targeting ADRA2B-Expressing Tumors
Creative Biolabs offers engineered CAR-T cells development services targeting ADRA2B-expressing tumors. Chimeric antigen receptor (CAR)-T cell immunotherapies, when specifically engineered to target ADRA2B-positive malignancies, demonstrate a remarkable capacity for potent antitumor activity. This innovative approach holds considerable promise in the oncology landscape. In rigorous in vitro co-culture assays, these engineered T cells effectively lysed glioblastoma cells, a highly aggressive form of brain cancer. Furthermore, the therapeutic potential was significantly corroborated in in vivo xenograft models, where these CAR-T cells were observed to reduce tumor volume by a substantial 65%. Critical to the validation of such targeted therapies, advanced immunofluorescence platforms provide essential insights into the precise mechanisms of target engagement and confirm the cytotoxic specificity of these modified immune cells. This comprehensive validation reinforces the potential for ADRA2B-targeted CAR-T cell therapy as a novel therapeutic modality.
ADRA2B-Reprogrammed Mesenchymal Stem Cells (MSCs)
Creative Biolabs offers ADRA2B-reprogrammed MSCs development services. MSCs that have been genetically engineered to overexpress ADRA2B antagonists are emerging as a promising therapeutic avenue for the treatment of various fibrotic diseases. In a compelling preclinical investigation utilizing a well-established liver fibrosis model, the intravenous administration of these engineered MSCs yielded notable results. Specifically, the MSCs were designed to secrete ADRA2B-neutralizing antibodies. Within a mere four-week period, this intervention led to a substantial reduction in collagen deposition, with observed decreases approaching 40%. This reduction in extracellular matrix accumulation suggests a significant amelioration of the fibrotic pathology. Furthermore, the efficacy and stability of such therapeutic transgenes can be meticulously monitored in real-time through comprehensive gene expression profiling services. These services provide crucial insights into the sustained potency of the genetic modification, thereby underpinning the clinical translatability of this novel therapeutic strategy.
Harnessing ADRA2B's mechanistic complexity requires cutting-edge tools and expert collaboration. Creative Biolabs' end-to-end solutions—from viral vector optimization to in vivo validation—equip researchers to accelerate discovery timelines. to design a tailored strategy for your ADRA2B-focused gene or cell therapy program.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
